boron/necrosis

Different isolates of Alternanthera mosaic virus (AltMV; Potexvirus), including four infectious clones derived from AltMV-SP, induce distinct systemic symptoms in Nicotiana benthamiana. Virus accumulation was enhanced at 15 °C compared to 25 °C; severe clone AltMV 3-7 induced systemic necrosis (SN)

Two experiments were conducted to determine the effects of dietary B on the production of cytokines following an endotoxin challenge. In both experiments, pigs were obtained from litters generated from sows fed low-B (control) or B-supplemented (5 mg/ kg, as-fed basis) diets. In Exp. 1 and 2, 28 and

The present study aimed to investigate the effects of the administration of boron on viability, apoptosis, and cell cycle of primary rat Sertoli cells (SCs) in vitro. SCs were aseptically isolated from 18-22-day-old male Sprague-Dawley (SD) rats. SCs were identified with immunofluorescence using

An acute study of boron trifluoride (BF3) in rats indicated the 4-hr LC50 to be 1.21 mg/liter. In a 2-week study, all animals exposed to 180 mg/m3 died prior to the sixth exposure, rats exposed at concentrations of 66 and 24 mg/m3 showed clinical signs of respiratory irritation, body weight gain

Sodium borocaptate (BSH) and boronophenylalanine (BPA) are two drugs that have been used clinically for boron neutron capture therapy (BNCT) of brain tumors. We previously have reported that hyperosmotic mannitol-induced disruption of the blood-brain barrier (BBB-D), followed by intracarotid (i.c.)

Immunoliposomes were prepared by conjugating anti-carcinoembryonic antigen (CEA) monoclonal antibody with liposomes containing [10B]compound. These immunoliposomes were shown to bind selectively to human pancreatic carcinoma cells (AsPC-1) bearing CEA on their surface. The cytotoxic effects of

Sulfhydryl boron hydride (BSH) (10B enriched) is presently used for boron neutron capture therapy of malignant gliomas. BSH must be close to the target cells to be effective in the inactivation of cell proliferation because of the short range of the reaction products (5-9 microns). Clinical

BACKGROUND Boron nitride nanotubes (BNNTs) represent a new opportunity for drug delivery and clinical therapy. The present work has the objective to investigate pectin-coated BNNTs (P-BNNTs) for their biocompatibility on macrophage cultures, since these cells are among the first components of the

A CD 344 rat glioma model currently used to investigate boron neutron capture therapy (BNCT) was used to demonstrate an increased survival rate after thermal neutron irradiation enhanced by administration of 10B-enriched polyhedral borane, Na2B12H11SH. To investigate the possible effects of BNCT on

OBJECTIVE To clarify the role of p53 in boron neutron capture therapy (BNCT) for oral squamous cell carcinoma (SCC), the effect of BNCT on oral SCC xenografts with either wild-type or mutant-type p53 was examined. METHODS Oral SCC cells expressing either wild-type (SAS/neo) or mutant-type p53

OBJECTIVE The aim of this study was to evaluate the effect of boron on 5-fluorouracil (5-FU)-induced oral mucositis in rats. METHODS Sixty-four male Wistar albino rats were injected with 5-FU on days 1 and 3. The right cheek pouch mucosa was scratched with the tip of an 18-G needle, dragged twice in

4-¹⁰B-Borono-2-¹⁸F-fluoro-L-phenylalanine (¹⁸F-FBPA) was developed for monitoring the pharmacokinetics of 4-¹⁰B-borono-L-phenylalanine (¹⁰B-BPA) used in boron neutron capture therapy (BNCT) with positron emission tomography (PET). The

OBJECTIVE Normal tissue tolerance of boron neutron capture irradiation using borocaptate sodium (NA2B12H11SH) in an epithermal neutron beam was studied. METHODS Large retriever-type dogs were used and the irradiations were performed by single dose, 5 x 10 dorsal portal. Fourteen dogs were irradiated

Boron, as borate, appears to have a role in partitioning metabolism between the glycolytic and pentose-shunt pathways. This effect results from the association of borate with 6-phosphogluconic acid, forming a virtual substrate that inhibits the action of 6-phosphogluconate dehydrogenase. In the

Neutron capture therapy with a new boron-porphyrin compound was tested in a rat brain tumor model. Although the concentration of boron in the tumor was too low to elicit a therapeutic effect, prominent histopathologic changes, such as necrosis, congestion and bleeding were observed in the tumors of